Problems Associated with Deprescribing of Proton Pump Inhibitors
Proton pump inhibitors (PPIs) are recommended as a first-line treatment for gastroesophageal reflux disease (GERD) and other acid related disorders. In recent years, concerns have been raised about the increasing prevalence of patients on long-term PPI therapy and inappropriate PPI use. It is well k...
Main Authors: | Holmfridur Helgadottir, Einar S. Bjornsson |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/21/5469 |
Similar Items
-
Who has the guts to deprescribe proton pump inhibitors? A pharmacist‐led intervention in a long‐term care facility setting
by: Rachel Tandun, et al.
Published: (2019-06-01) -
Discussing proton pump inhibitor deprescribing: the views of Danish GPs and older patients
by: Wade Thompson, et al.
Published: (2020-08-01) -
Deprescribing of Inappropriately Consumed Proton Pump Inhibitors and its Clinical Consequences
by: Apoorva Rachana Kulkarni, et al.
Published: (2021-08-01) -
Deprescribing and Optimal Selection of Proton Pump Inhibitors (Contributions of the 26th United Russian Gastroenterology Week)
by: V. T. Ivashkin, et al.
Published: (2020-12-01) -
Influence of Proton Pump Inhibitor Use in Gastrointestinal Polyps
by: Wen-Hung Hsu, et al.
Published: (2010-02-01)